Recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population.
Not exact matches
These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from
generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most
recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
Indeed, five other Valeant
drugs singled out in
recent Congressional hearings are off - patent but have no
generic competitors yet.
Even after the outrage the
drug faced, the price of the branded EpiPen hasn't changed, Duhigg noted on a
recent trip to the pharmacy, though the company did introduce a
generic that has a list price of $ 300.
The world's largest
drug manufacturer is facing steep competition from a slew of smaller
generic players, and the
recent loss of patent protection on its major branded
drug, Copaxone, is threatening Teva's profit margins.
Early Monday, Allergan plc Ordinary Shares (NYSE: AGN)-- one of the world's largest pharmaceutical companies that produces branded and
generic drugs, and performs pharmaceutical research and development — announced its
recent acquisition of Zeltiq Aesthetics.
An Indian
generic drug company on Monday urged a federal appeals court to reconsider a
recent decision that revived a patent infringement case against Google LLC, saying the ruling could spur «vexatious lawsuits» by makers of brand - name pharmaceutical products.
The chairman of its GP committee's clinical and prescribing sub-committee, Bill Beeby, said: «The PAC report acknowledges that there has been a substantial increase in prescribing
generic drugs in
recent years and with just over two per cent of the overall
drugs bill identified as potential savings it shows that the official advice is already being heeded.»
Prices for some
generic drugs have increased in
recent years, adversely affecting patients who rely on them.
However, because the gains which have been made in reducing health care spending are largely attributable to price dynamics (such as reduced or no growth in physician reimbursement rates, and high use of cheaper
generic drugs), the authors warn that any future economic recovery might reverse the progress that has been made in
recent years.
Nexium and Prevacid (which is also available as a
generic drug, lansoprazole) are the two most popular proton pump inhibitors, according to the most
recent government data.
We were originally attracted to TEVA because of its leading position in
generic drugs, its free cash flow generation from its branded
drug division, its
recent dividend growth, and its cheap price to our estimation of its intrinsic value.
While pharmaceutical giant Pfizer is trying to get the Supreme Court of Canada to take a second look at its
recent judgment voiding its patent on Viagra, it's trying to use the same decision to quash a case in the Federal Court involving another
generic drug maker.
A
recent Supreme Court ruling is limiting court actions by injured patients who have filed claims against manufacturers of
generic drugs.